Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: Evidence from an italian spontaneous, prospective, and observational study (the TY-STOP study)

JAMA Neurology

Volumn 71, Issue 8, 2014, Pages 954-960

  Clerico, Marinella ^a   Schiavetti, Irene ^b   De Mercanti, Stefania F ^a   Piazza, Federico ^a   Gned, Dario ^a   Morra, Vincenzo Brescia ^c   Lanzillo, Roberta ^c   Ghezzi, Angelo ^d   Bianchi, Anna ^d   Salemi, Giuseppe ^e   Realmuto, Sabrina ^e   Sola, Patrizia ^f   Vitetta, Francesca ^f   Cavalla, Paola ^g   Paolicelli, Damiano ^h   Trojano, Maria ^h   Sormani, Maria Pia ^b   Durelli, Luca ^a  

^a SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d Sant'Antonio Abate Hospital   (Italy)

^e UNIVERSITY OF PALERMO   (Italy)

^f UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^g UNIVERSITY OF TURIN   (Italy)

^h UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; FINGOLIMOD; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; ATAXIC APHASIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; FEMALE; FLU LIKE SYNDROME; GENERALIZED EPILEPSY; HUMAN; HYPERTRANSAMINASEMIA; INJECTION SITE REACTION; INTENTION TO TREAT ANALYSIS; JC VIRUS; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROSPECTIVE STUDY; RECURRENCE RISK; TREATMENT OUTCOME; CLINICAL TRIAL; ITALY; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECURRENT DISEASE;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; ITALY; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME;

EID: 84905968845     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.1200     Document Type: Article

References (30)

1. Polman CH, O'Connor PW, Havrdova E, et al AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910.
2. Rudick RA, Stuart WH, Calabresi PA, et al SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):911-923.
3. Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009;8(3):254-260.
4. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a formultiple sclerosis. N Engl J Med. 2005;353(4):369-374. (Pubitemid 41132341)
5. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005;353(4):375-381. (Pubitemid 41132342)
6. Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis. Lancet Neurol. 2010;9(4):438-446.
7. European Medicines Agency. European Medicines Agency recommends additional measures to better manage risk of progressive multifocal leukoencephalopathy (PML) with Tysabri. http://www.ema.europa.eu/ema/index.jsp? curl=pages/news-and-events/news/2010/01/news-detail-000987.jsp&mid= WC0b01ac058004d5c1. Accessed April 14, 2014.
8. Vellinga MM, Castelijns JA, Barkhof F, Uitdehaag BM, Polman CH. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology. 2008;70(13, pt 2):1150-1151. (Pubitemid 351464749)
9. Stüve O, Cravens PD, Frohman EM, et al. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology. 2009;72(5):396-401.
10. Kaufman MD, Lee R, Norton HJ. Course of relapsing-remitting multiple sclerosis before, during and after natalizumab. Mult Scler. 2011;17(4):490-494.
11. O'Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 2011;76(22):1858-1865.
12. Havla J, Gerdes LA, Meinl I, et al. De-escalation from natalizumab in multiple sclerosis. J Neurol. 2011;258(9):1665-1669.
13. Rinaldi F, Seppi D, Calabrese M, Perini P, Gallo P. Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis. Mult Scler. 2012;18(11):1640-1643.
14. Melis M, Cocco E, Frau J, et al. Post-natalizumab clinical and radiological findings in a cohort of multiple sclerosis patients. Neurol Sci. 2014;35(3):401-408.
15. Jokubaitis VG, Li V, Kalincik T, et al MSBase Study Group. Fingolimod after natalizumab and the risk of short-term relapse. Neurology. 2014;82(14):1204-1211.
16. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 1983;33(11):1444-1452. (Pubitemid 14237132)
17. Sormani MP, Bruzzi P, Miller DH, Gasperini C, Barkhof F, Filippi M. Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model. J Neurol Sci. 1999;163(1):74-80. (Pubitemid 29155420)
18. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab- associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870-1880.
19. Sørensen PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler. 2012;18(2):143-152.
20. Agenzia Italiana del Farmaco. Regime di rimborsabilita' e prezzo di vendita del medicinale Gilenya (fingolimod cloridrato). Determinazione 8 Novembre 2011. Determinazione/C n. 2701/2011. http://www.gazzettaufficiale.it/ eli/id/2011/11/22/11A14935/sg;jsessionid=kTGAR8g+xNRZU1Dm2HYrqg-.ntc-as2-guri2a. Accessed May 19, 2014.
21. Giovannoni G. Multiple sclerosis research: natalizumab PML risk update: February 2014. http://multiple-sclerosis-research.blogspot.co.uk/2014/03/ natalizumab-pml-risk-update-february.html. Accessed April 14, 2014.
22. Gobbi C, Meier DS, Cotton F, et al. Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial. BMC Neurol. 2013;13:101. doi:10.1186/1471-2377-13-101.
23. Rossi S, Motta C, Studer V, et al. Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab. Eur J Neurol. 2013;20(1):87-94.
24. Havla J, Tackenberg B, Hellwig K, et al. Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis. J Neurol. 2013;260(5):1382-1387.
25. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis, I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43(4):655-661.
26. Comi G, Filippi M, Wolinsky JS; European/Canadian Glatiramer Acetate Study Group. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol. 2001;49(3):290-297. (Pubitemid 32202781)
27. Kappos L, Radue E-W, O'Connor P, et al FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387-401.
28. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502- 1517.
29. Phan-Ba R, Belachew S, Outteryck O, et al. The earlier, the smaller, the better for natalizumab-associated PML: in MRI vigilance veritas? Neurology. 2012;79(10):1067-1069.
30. Wattjes MP, Richert ND, Killestein J, et al. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy. Mult Scler. 2013;19(14):1826-1840.